SGP Schering-Plough Corporation Loading... : Investor Sentiment and Bull/Bear Views
Loading chart...
Top Calls
No data yet
Price change since each call, adjusted for long/short direction. Results calculated:
Feed
Time
Author
Thesis
Company / ticker
Signal
Since call
Position
Source
16:05
Feb 12
Feb 12
Morgan Stanley
Zetia profits replace Claritin patent cliff
Hynes was out of consensus in viewing Schering-Plough's Zetia as a complementary, new-mechanism cholesterol drug that could replace the profits lost when Claritin went off patent in 2002. She expected Zetia's launch to offset the high-margin patent cliff, and over the decade the thesis proved correct despite faster-than-expected patent erosion and earnings pressure; Schering-Plough became one of the best pharmaceutical investments of that decade.
SGP
Schering-Plough Corporation
Long
1ST
—
—
About SGP Investor Commentary
Across the available history and selected sources, Buzzberg tracks SGP (Schering-Plough Corporation) across 2 sources: 1 bullish vs 0 bearish calls from 2 authors. Historical directional balance: 50% = 100 × (bullish − bearish) / all deduplicated idea records, including other directions. This is neither a probability of a price rise nor the share of bullish authors. 2 total trade ideas tracked. Past 7 days, before deduplication: 1 other directions. Latest voices: Jean Hynes.